Rheumatologists can diagnose Ehlers-Danlos syndrome, and for the most common form, hypermobile EDS, they are often the specialists best positioned to do so. The catch is that not every rheumatologist is comfortable making the call. EDS sits at an awkward intersection of rheumatology, genetics, and several other specialties, and whether you get a confident diagnosis or a shrug depends heavily on how much experience your particular doctor has with connective tissue disorders. The story behind why this question is so common reveals a lot about how the condition is identified, missed, and managed.
Why Rheumatologists Are a Natural Fit
Ehlers-Danlos syndrome is a group of heritable connective tissue disorders, and the hypermobility type (hEDS) accounts for an estimated 80% or more of all cases.1ScienceDirect (Elsevier / Joint Bone Spine). Ehlers–Danlos syndrome in rheumatology: Diagnostic and therapeutic challenges The hallmark of hEDS is generalized joint hypermobility combined with chronic pain, recurrent dislocations or subluxations, and a range of other connective tissue signs. Joint hypermobility and musculoskeletal pain are bread-and-butter rheumatology territory, so these patients frequently end up in a rheumatologist’s office, either through referral or after years of bouncing between other doctors.
A rheumatologist’s training equips them to perform the Beighton score (a standardized measure of joint flexibility), assess skin extensibility, screen for systemic features, and rule out inflammatory or autoimmune conditions that can mimic EDS symptoms. Primary care providers are encouraged to become familiar with hEDS evaluation and to refer to connective tissue disorder specialists when the picture gets complicated.2PubMed Central. Hypermobile Ehlers Danlos for the Primary Care Provider In practice, “connective tissue disorder specialist” usually means a rheumatologist or a geneticist, and which one you see first often comes down to local availability and referral patterns more than any hard clinical rule.
How hEDS Is Actually Diagnosed
There is no blood test or genetic marker for hypermobile EDS. Diagnosis is entirely clinical, based on the 2017 international classification criteria, which were specifically revised to sharpen the distinction between hEDS and other joint hypermobility disorders.3PubMed. The 2017 international classification of the Ehlers-Danlos syndromes The criteria require three things to be present simultaneously: generalized joint hypermobility (usually measured by the Beighton score), a set of systemic features involving skin, musculoskeletal, and family history findings, and the exclusion of other diagnoses that could explain the symptoms.
A rheumatologist who knows these criteria can walk through them in a thorough office visit. The physical exam matters enormously. The doctor checks how far your joints extend, whether your skin is unusually stretchy or velvety, whether you have signs like stretch marks disproportionate to your body history, piezogenic papules on your heels, or a positive family history. They also need to rule out other connective tissue conditions and inflammatory arthritis, which is squarely in a rheumatologist’s wheelhouse.
The practical challenge is that many rheumatologists were not trained on these criteria in residency. EDS was historically treated as vanishingly rare and outside the mainstream rheumatology curriculum. A rheumatologist who primarily sees rheumatoid arthritis and lupus may not feel confident applying hEDS criteria, even though the skill set overlaps. This is why patients often seek out rheumatologists who specifically list EDS or hypermobility in their areas of interest.
When You Need a Geneticist Instead
The 2017 classification recognizes 13 subtypes of EDS, and all but hEDS have identified genetic causes that can be confirmed through molecular testing. Vascular EDS, for example, involves mutations in the COL3A1 gene and carries serious risks of arterial rupture and organ perforation. Classical EDS involves mutations in COL5A1 or COL5A2. Kyphoscoliotic EDS results from mutations in the PLOD1 gene, which leads to a deficiency in an enzyme involved in collagen processing.4PubMed Central. Rare Cases of PLOD1-Related Kyphoscoliotic Ehlers-Danlos Syndrome in a Korean Family Identified by Next Generation Sequencing For these rarer subtypes, a medical geneticist is the appropriate specialist to order and interpret genetic testing, confirm the diagnosis, and counsel the patient and family about inheritance patterns.
This is where the referral landscape gets messy. Because the term “Ehlers-Danlos syndrome” covers both the common hypermobility type and the rarer genetic subtypes, referrals to genetics clinics for suspected hEDS have been rising steadily, even though there is no molecular test to run. Without nationally recognized referral guidelines, individual institutions have been left to develop their own policies for managing this influx.5Genetics in Medicine Open. An evaluation of practices and policies used in genetics clinics across the United States to manage referrals for Ehlers-Danlos and hypermobility syndromes The result is long wait times at genetics clinics for patients who may not actually need a geneticist and could have been diagnosed by a rheumatologist using the clinical criteria.
A reasonable approach, and one that many EDS-literate providers follow, is to start with a rheumatologist for the clinical evaluation. If the presentation suggests a subtype other than hEDS, or if there are red flags for vascular involvement, fragile skin with atrophic scarring, or features that do not fit the hEDS criteria cleanly, a genetics referral makes sense. For the majority of patients whose picture fits hEDS, a rheumatologist can make the diagnosis and begin coordinating care without the genetics bottleneck.
The Diagnostic Odyssey
Understanding why people ask “can a rheumatologist diagnose EDS” requires understanding how difficult getting any diagnosis can be. In a large survey of people with hEDS, respondents reported seeing an average of about 16 clinicians before receiving a diagnosis, and the average time from symptom onset to diagnosis was roughly 10 years.6Genetics in Medicine Open. Comorbidity, misdiagnoses, and the diagnostic odyssey in patients with hypermobile Ehlers-Danlos syndrome Those numbers are staggering and reflect how poorly recognized hEDS remains across many areas of medicine.
Part of the delay stems from the sheer number of co-existing conditions that accompany hEDS. In that same survey, the average patient reported more than 10 additional diagnoses. The most common were anxiety, depression, migraines, postural orthostatic tachycardia syndrome (POTS), and irritable bowel syndrome.6Genetics in Medicine Open. Comorbidity, misdiagnoses, and the diagnostic odyssey in patients with hypermobile Ehlers-Danlos syndrome Each of those conditions tends to be evaluated by a different specialist, and none of them individually screams “connective tissue disorder.” The patient sees a cardiologist for the racing heart, a gastroenterologist for the gut issues, and a psychiatrist for the anxiety, but nobody connects the dots.
The misdiagnosis problem goes beyond just missing the underlying condition. A retrospective review of over 400 patients clinically diagnosed with hEDS found that roughly 94% had previously received at least one psychiatric mischaracterization, such as being told their symptoms were fabricated, “in their head,” or attention-seeking.7PubMed Central. The Incidence of Misdiagnosis in Patients with Ehlers–Danlos Syndrome About 88% were told they were making up their symptoms, and about 67% received a conversion disorder label. These are not just diagnostic errors but experiences that erode trust in the medical system and make patients hesitant to keep seeking answers.
The Evolving Criteria and the hEDS-HSD Boundary
One reason diagnosis is so fraught is that the 2017 criteria, while an improvement over earlier systems, drew a sharper line between hEDS and what is now called hypermobility spectrum disorder (HSD). HSD captures people who have symptomatic joint hypermobility but do not meet the full checklist for hEDS. The intent was to improve diagnostic specificity, but some clinicians and researchers have argued the criteria may be too strict.
A retrospective study from an Italian reference center evaluated over 300 patients who had previously been diagnosed with the hypermobility type of EDS under older criteria (the Villefranche and Brighton systems). When the 2017 criteria were applied, a meaningful proportion no longer qualified for hEDS and instead fell into the HSD category. The authors proposed that the criteria should be relaxed to include more of these patients.8Wiley Online Library. Looking back and beyond the 2017 diagnostic criteria for hypermobile Ehlers-Danlos syndrome: A retrospective cross-sectional study from an Italian reference center This debate matters practically because patients with HSD often experience symptoms just as severe as patients with hEDS, yet may find it harder to access specialized care or get their condition taken seriously.
For someone sitting in a rheumatologist’s office, this means that even an EDS-knowledgeable doctor might tell you that you have HSD rather than hEDS. That does not mean your symptoms are less real or that treatment would differ substantially. The management for both conditions centers on physical therapy, pain management, and addressing associated conditions. But it can feel like a frustrating distinction when you have been seeking validation for years.
The Search for a Genetic Basis of hEDS
The reason hEDS remains a clinical diagnosis is that the responsible gene or genes have not been definitively identified. That has been one of the longest-standing puzzles in connective tissue genetics, and it is only now beginning to yield clues. A 2025 study using whole-exome sequencing of 200 hEDS patients identified rare variants across a family of genes called kallikreins, including a recurring variant in KLK15 that appeared to segregate in multiple families and was shown to affect connective tissue in functional experiments.9iScience. KLK15 alters connective tissues in hypermobile Ehlers-Danlos syndrome
A separate genome-wide association study meta-analysis turned up two genetic regions reaching statistical significance in hEDS, including one near a gene called ACKR3 on chromosome 2 that appears to be involved in neuroimmune and pain signaling pathways. The study also found that common genetic variants in a region containing SLC39A13, a zinc transporter already implicated in a rare form of EDS, were associated with hEDS risk. Perhaps most revealing, the analysis found significant genetic overlap between hEDS and a cluster of related conditions including chronic fatigue syndrome, fibromyalgia, depression, anxiety, autism spectrum disorder, migraine, and gastrointestinal diseases.10PubMed Central. Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos Syndrome: Insights from Genome-Wide Association Study Meta-analysis
These findings are early-stage and do not yet change how hEDS is diagnosed in the clinic. But they are encouraging because they suggest the condition has a real, identifiable genetic architecture, even if it turns out to be complex rather than caused by a single gene. If validated, future genetic tests could eventually move hEDS diagnosis from purely clinical criteria to something more definitive, and they could reshape which specialist is considered the primary diagnostician.
Beyond the Joints
One of the reasons a rheumatologist alone may not be enough, even when they make the correct diagnosis, is that hEDS tends to involve far more than joints. Gastrointestinal symptoms are common and often severe, with high rates of functional gut disorders, reflux, nausea, and disordered eating patterns.11PubMed. Gastrointestinal Manifestations and Nutrition Support in Hypermobile Ehlers-Danlos, Postural Orthostatic Tachycardia, and Mast Cell Activation Syndromes Many patients also develop POTS, which causes a dramatic spike in heart rate upon standing, along with dizziness and fatigue. A subset experience symptoms consistent with mast cell activation syndrome (MCAS), which involves episodes of flushing, hives, or gastrointestinal distress. These three conditions, hEDS, POTS, and MCAS, cluster together frequently enough that clinicians increasingly evaluate for all three when one is present.12PubMed. Gastrointestinal Manifestations of Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: A Mentored Review
An expert review from the American Gastroenterological Association recently outlined principles for evaluating and managing gut symptoms and autonomic or immune dysfunction specifically in hEDS and HSD patients.13Clinical Gastroenterology and Hepatology. AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review The existence of formal gastroenterology guidance for a condition traditionally seen as a rheumatology or genetics issue reflects how far the understanding of hEDS has expanded. Getting the diagnosis is step one; coordinating care across cardiology, gastroenterology, physical therapy, and sometimes neurology is step two, and it is arguably the harder part.
The Pain Picture Is More Complicated Than Loose Joints
Chronic pain is the symptom that drives most hEDS patients to seek help, and it does not always behave the way you would expect from a joint disorder. Research in adolescents with hEDS or HSD has found signs of central sensitization, meaning their nervous systems amplify pain signals beyond what the tissue damage alone would explain. Compared to healthy controls, adolescents with hEDS/HSD showed significantly lower pressure pain thresholds across multiple muscle groups, and their pain-inhibition responses after exercise were blunted.14PubMed Central. Exploring signs of central sensitization in adolescents with hypermobility Spectrum disorder or hypermobile Ehlers‐Danlos syndrome
This matters for diagnosis because the pain a patient reports may seem out of proportion to what the rheumatologist observes on physical exam. A doctor unfamiliar with central sensitization in hEDS might attribute the complaint to anxiety or catastrophizing rather than recognizing it as a known feature of the condition. The genetic overlap between hEDS and conditions like fibromyalgia and chronic fatigue syndrome, noted in the genome-wide analysis discussed earlier, reinforces the idea that pain processing abnormalities are not incidental to hEDS but are part of its biology.10PubMed Central. Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos Syndrome: Insights from Genome-Wide Association Study Meta-analysis
Diagnosing Children and Adolescents
Evaluating joint hypermobility in children adds another layer of complexity. Children are naturally more flexible than adults, and the Beighton score thresholds used for adults can overidentify hypermobility in young kids. A diagnostic framework for pediatric joint hypermobility established a minimum age of five years for meaningful assessment, since infants and toddlers do not have sufficient skeletal maturity for the results to be clinically useful.15PubMed Central. Pediatric joint hypermobility: a diagnostic framework and narrative review For adolescents who have not yet finished growing, hypermobility should be compared against age- and sex-specific reference data rather than adult norms.
Once an adolescent reaches biological maturity, defined by skeletal maturity and a growth velocity below one centimeter per year, the standard 2017 adult criteria become applicable.15PubMed Central. Pediatric joint hypermobility: a diagnostic framework and narrative review A pediatric rheumatologist is generally the right specialist for children suspected of having hEDS, but as with adult rheumatologists, familiarity with the specific criteria varies widely. Parents seeking evaluation for a child often face even longer wait times and fewer available specialists than adults do.
Cardiovascular Screening After Diagnosis
A question that comes up after diagnosis is whether people with hEDS need heart imaging. The answer is not straightforward, and cardiologists and geneticists do not fully agree. One systematic review of echocardiogram data in hEDS and HSD patients found that about 15% had some degree of thoracic aortic dilation, with a higher rate in those with hEDS specifically compared to those with HSD.16PubMed Central. Cardiovascular manifestations of hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders A separate retrospective cohort study from a dedicated EDS clinic found a lower prevalence, with aortic root dilation in about 3% of hEDS patients and under 1% of HSD patients.17PubMed Central. Cardiac defects of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective cohort study
Given this range, some experts have recommended against routine echocardiographic screening in hEDS patients who have no cardiac symptoms and no family history of aortic problems.18PubMed. Cardiac involvement in classical or hypermobile Ehlers-Danlos syndrome is uncommon Others argue that the non-trivial rates justify at least a baseline echocardiogram. Your rheumatologist or geneticist should weigh your individual risk profile, including family history and the presence of any murmurs or other cardiac findings, when deciding whether to order imaging.
What Happens After Diagnosis
Getting a name for the condition is a critical milestone, but management is where the real work begins. For hEDS, there is no medication that fixes the underlying connective tissue problem. Treatment is centered on physical therapy, ideally with a therapist who understands hypermobility and knows to avoid pushing joints past their unstable range. A case report of an hEDS patient with upper cervical spine instability documented a 12-month individualized rehabilitation program that included motor control retraining and progressive strengthening. The patient experienced a 55% reduction in pain, a roughly 50% improvement in function, and regained partial independence.19JOSPT Cases. Physical Therapy Management of Upper Cervical Spine Instability in a Patient With Hypermobile Ehlers–Danlos Syndrome: A Case Report That is one patient, not a clinical trial, but it illustrates the kind of targeted, long-term rehabilitation that makes a difference when it is done well.
Beyond physical therapy, management often involves coordinating with other specialists for the associated conditions. POTS may require a cardiologist or autonomic specialist. Gastrointestinal symptoms may need a gastroenterologist familiar with the hEDS-POTS-MCAS overlap. Pain management might involve a pain specialist who understands central sensitization. The rheumatologist who made the diagnosis may continue to play a coordinating role, but in many cases, the patient becomes their own project manager, keeping multiple providers on the same page.
Navigating the System with Overlapping Conditions
The healthcare navigation burden falls disproportionately hard on certain populations. Autistic individuals with hEDS face compounded barriers, including difficulty communicating symptoms in ways clinicians expect, sensory challenges in clinical environments, and a higher likelihood of having their physical symptoms attributed to their neurodevelopmental condition rather than investigated independently.20PubMed Central. The Complexities of Navigating the Healthcare System as an Autistic Individual with Ehlers-Danlos Syndrome: A Patient Perspective The genetic correlation between hEDS and autism spectrum disorder identified in recent research suggests this overlap is not coincidental, making it all the more important that clinicians screen for connective tissue symptoms in autistic patients who present with chronic pain or hypermobility.
If you are trying to get an evaluation, the most practical step is to look for a rheumatologist who explicitly treats EDS or hypermobility disorders. EDS patient advocacy organizations maintain provider directories that can help. When calling to schedule, ask whether the provider uses the 2017 diagnostic criteria and whether they regularly evaluate for hEDS. If your rheumatologist suspects a rarer subtype, they should refer you onward to genetics. And if the first rheumatologist you see is dismissive or unfamiliar with the condition, that reflects a gap in their specific experience, not the limits of what rheumatology can do.